Dr. Maya Prakash Singh is a research scientist/microbiologist with over 35 years of work experience in pharmaceutical and medical device multinational companies located in Canada and USA. Dr. Singh is a BITian (1973 batch of Pharmaceutical Sciences) and has had an illustrious career in the field of drug discovery and development with specific focus on novel antimicrobial agents. His scientific career encompasses: Associate Professor at BITS Pilani (1983-‘84), AHFMR Post-Doctoral Fellow at the University of Alberta in Edmonton, Canada (1984-‘86), Senior Scientist/Group Leader at SynPhar Laboratories, a joint venture with Taiho Pharma of Japan (1986-‘91), Principal Research Scientist at Lederle Laboratories/Wyeth/Pfizer in Pearl River, New York (1992-2010), Senior Scientist at Novozyme in Virginia (2010-‘12), and Manager of Scientific Research at CareFusion/Becton, Dickinson and Company (BD) in Chicago/New Jersey (2012-‘20). Dr. Singh retired in early 2021 and is settled in New York, USA.
Dr. Singh obtained his B Pharm degree from BIT Mesra (‘77), M Pharm (‘79) and PhD (‘83) from Jadavpur University, Kolkata. He did a post-doctoral research on novel beta-lactam antibiotics at the University of Alberta in Edmonton, Canada (‘84-‘86). He has authored/co-authored 7 patents and 80 peer reviewed publications. He is an Emeritus Member of the American Society for Microbiology (ASM).
Widespread use of antibiotics has led to the emergence of microorganisms resistant to one or more antibiotics, and similar concern has been raised for widely used antiseptics and disinfectants. The possible correlation between antiseptic and antibiotic resistance is of major concern, and regulatory bodies are requiring manufacturers to conduct resistance development studies with certain biocides/antiseptics and to assess the susceptibility of biocide-exposed microorganisms to commonly used antibiotics. Since there is no standard protocol or guidance for such studies manufacturers have to develop a method that will meet the regulatory requirements for product approval. This talk will discuss the possible approaches based on the experience with a widely used antiseptic agent, Chlorhexidine Gluconate (CHG).
An incredible Journey of 50 years of the Department
Come, see and celebrate the Golden Jubilee of the Department with us
16th -18th December 2022
Department of Pharmaceutical Science & Technology
Birla Institute of Technology, Mesra, Ranchi 835215 (JH), India